UK clears Foundayo, a new obesity drug
2026-08-11
Regulatory approval, not public demand, is now pushing the obesity drug boom into a new phase in the UK. Foundayo, an oral weight loss pill from Eli Lilly, has been cleared for use, extending the company’s influence from its injectable Mounjaro into the daily tablet market and tightening its grip on incretin‑based therapies.
This pill matters because it turns a specialist injection story into something closer to routine primary care. Foundayo targets the same gut hormone pathways as Mounjaro, acting on GLP‑1 and related incretin signalling to slow gastric emptying and influence hypothalamic appetite control, a mechanism that has already reshaped treatment algorithms for obesity and type 2 diabetes. Early trial data showed double‑digit percentage reductions in body weight for many participants, a scale of effect that once belonged only to bariatric surgery.
The uncomfortable truth is that this convenience will sharpen fault lines over access and cost. Health services must decide how to leverage a branded pill that may require long‑term, possibly lifelong, use to sustain weight loss, while tracking known risks such as gastrointestinal effects and rare pancreatitis. For rivals, the approval deepens Eli Lilly’s moat in metabolic disease; for patients and prescribers, it turns a once‑niche hormone pathway into a mass‑market option that will test how far societies are willing to medicalise weight.
Loading...
